(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-2.07% ¥ 3 740.00
Live Chart Being Loaded With Signals
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies...
Stats | |
---|---|
Dzisiejszy wolumen | 323 000 |
Średni wolumen | 176 355 |
Kapitalizacja rynkowa | 283.28B |
EPS | ¥0 ( 2024-04-10 ) |
Następna data zysków | ( ¥0 ) 2024-07-11 |
Last Dividend | ¥42.50 ( 2023-08-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.28 |
ATR14 | ¥1.742 (0.05%) |
Wolumen Korelacja
Hisamitsu Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hisamitsu Pharmaceutical Korelacja - Waluta/Towar
Hisamitsu Pharmaceutical Finanse
Annual | 2023 |
Przychody: | ¥141.71B |
Zysk brutto: | ¥78.97B (55.73 %) |
EPS: | ¥181.62 |
FY | 2023 |
Przychody: | ¥141.71B |
Zysk brutto: | ¥78.97B (55.73 %) |
EPS: | ¥181.62 |
FY | 2022 |
Przychody: | ¥128.33B |
Zysk brutto: | ¥72.70B (56.65 %) |
EPS: | ¥148.00 |
FY | 2022 |
Przychody: | ¥120.19B |
Zysk brutto: | ¥70.07B (58.30 %) |
EPS: | ¥118.92 |
Financial Reports:
No articles found.
Hisamitsu Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0.250 (N/A) |
¥0 (N/A) |
¥0.250 (N/A) |
¥0 (N/A) |
¥42.50 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-02-23 |
Last Dividend | ¥42.50 | 2023-08-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | ¥1 175.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.73 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.60 | |
Div. Directional Score | 7.69 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8200.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
7590.T | Ex Dividend Junior | 2024-01-18 | Annually | 0 | 0.00% | |
6785.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
6125.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4829.T | Ex Dividend Knight | 2024-05-30 | Annually | 0 | 0.00% | |
4043.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3254.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2288.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9142.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7994.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0986 | 1.500 | 8.03 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0425 | 1.200 | 8.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0524 | 1.500 | -0.529 | -0.793 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.45 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00455 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 731.56 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00565 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.557 | 1.000 | 4.05 | 4.05 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0929 | 1.000 | -0.142 | -0.142 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.86 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 10.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.30 | 1.000 | 8.05 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0524 | 2.50 | -0.340 | -0.793 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.27 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.894 | 1.500 | 7.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0514 | 1.000 | -1.216 | 0 | [0.1 - 0.5] |
Total Score | 4.60 |
Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej